Calretinin ELISA Test

Calretinin ELISA Test


In the realm of modern medicine, advanced diagnostic techniques play a pivotal role in enhancing our understanding of complex diseases and enabling precise patient care. Among these, the Calretinin Enzyme-Linked Immunosorbent Assay (ELISA) test has emerged as a groundbreaking tool in neurological research and clinical diagnostics. This article aims to provide an in-depth exploration of the Calretinin ELISA test, its principles, applications, and significance in identifying neurodegenerative disorders and malignant tumors.

Understanding the Calretinin Protein

Calretinin is a calcium-binding protein expressed in various tissues, particularly in neurons and certain tumors. In the central nervous system, calretinin plays a crucial role in modulating intracellular calcium levels, regulating synaptic plasticity, and influencing neuronal excitability. Its presence in specific neuronal subtypes serves as a marker for the identification of neurons involved in diverse neurological processes.

Principles of the Calretinin ELISA Test

The Calretinin ELISA test is a sensitive and specific immunoassay designed to detect and quantify calretinin protein levels in biological samples such as cerebrospinal fluid (CSF) or tissue homogenates. The assay is based on the principles of antigen-antibody recognition, utilizing specific antibodies that selectively bind to calretinin.

Calretinin immunohistochemistry on a rectal suction biopsy for suspicion of HD.Figure 1. Calretinin immunohistochemistry on a rectal suction biopsy for suspicion of HD. (Guinard-Samuel V, et al.; 2009)

The test involves several key steps:

  • Sample Collection: CSF or tissue samples are collected from patients suspected of having neurodegenerative disorders or tumors. Proper sample handling and storage are crucial to maintain the integrity of the calretinin protein.
  • Sample Preparation: The collected samples undergo processing to extract the calretinin protein. This step involves homogenization and, in some cases, purification to remove potential interfering substances.
  • Coating: A microplate is coated with an antibody specific to calretinin, creating a solid-phase surface that can capture the target protein from the sample.
  • Incubation: The prepared samples, along with appropriate controls, are added to the microplate wells and allowed to incubate. During this phase, calretinin present in the samples binds to the immobilized antibody on the plate.
  • Washing: After incubation, the microplate is thoroughly washed to remove any unbound components and contaminants.
  • Detection: A secondary antibody conjugated with an enzyme is introduced to the wells. This secondary antibody recognizes a different site on the calretinin protein, leading to the formation of an antigen-antibody-enzyme complex.
  • Substrate Addition: A substrate specific to the enzyme is added to the microplate. When the enzyme reacts with the substrate, it generates a measurable signal (e.g., color change) that is directly proportional to the amount of calretinin present in the sample.
  • Measurement: The optical density or absorbance of the generated signal is measured using a spectrophotometer. This data is used to calculate the concentration of calretinin in the original sample.

Applications of Calretinin ELISA Test

The Calretinin ELISA test has significant applications in both research and clinical settings:

  • Neurodegenerative Disorders: In neurology, the test helps identify abnormal calretinin levels associated with neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's disease. Aberrant calretinin expression can serve as an early diagnostic marker, aiding in disease detection and monitoring disease progression.
  • Malignant Tumors: In oncology, the Calretinin ELISA test is used to detect elevated calretinin levels in malignant tumors, particularly mesotheliomas and ovarian carcinomas. Calretinin acts as a specific biomarker for these tumors, facilitating accurate diagnosis and differentiation from other cancer types.
  • Biomarker Discovery: Researchers utilize the Calretinin ELISA test to explore novel biomarkers for various neurological conditions. By analyzing calretinin levels in different experimental groups, scientists can gain valuable insights into disease mechanisms and potential therapeutic targets.

Significance of the Calretinin ELISA Test

The excellent sensitivity, specificity, and repeatability of the calretinin ELISA test are key factors in demonstrating its value. Because it can measure the quantities of calretinin in biological samples, it gives doctors and researchers the information they need to make decisions about patient care and experiment results.

Early and precise identification of neurodegenerative illnesses enables clinicians to intervene quickly, improve patient outcomes, and treat the disease more effectively. Similar to this, in oncology, the Calretinin ELISA test's early diagnosis of malignant tumors enables proper treatment planning, improving patient quality of life and survival rates.

The Calretinin ELISA test is used in research to help reveal the complex mechanisms underlying neurological diseases. This assay's discovery of novel biomarkers aids in the creation of tailored medicines, which may completely alter how cancer and neurological disorders are treated.


A noteworthy development in the area of medical diagnostics is the calretinin ELISA test. Its capacity to precisely measure calretinin levels has created new opportunities for neurology and oncology, giving both patients and researchers alike hope. The Calretinin ELISA test's potential impact on bettering patient treatment and comprehending neurological illnesses remains immeasurable with ongoing developments and study. This ground-breaking test promises to advance our understanding of intricate neural functions and support the creation of cutting-edge therapeutic approaches as technology advances.


  1. Guinard-Samuel V, et al.; Calretinin immunohistochemistry: a simple and efficient tool to diagnose Hirschsprung disease. Mod Pathol. 2009, 22(10):1379-84.
The service is for research only, not for clinical use.
Online Inquiry